Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease

Mise à jour : Il y a 4 ans
Référence : NCT01075178

Femme et Homme

Extrait

Retrospective medical record review study of specific adverse events in children with congenital heart disease who received palivizumab for prophylaxis of serious respiratory syncytial virus infection and control subjects that did not receive palivizumab


Critère d'inclusion

  • Severe Respiratory Syncytial Virus Infection


Liens